放射性药物治疗:快速增长、日益挑战与专业人才的迫切需求
该SNMMI立场文件指出,随着神经内分泌肿瘤和前列腺癌的诊疗一体化获批,放射性药物治疗(RPT)应用扩大且近期在多瘤种中有望进一步扩展。文件强调核医学专业人员通过特定培训、教育、监管指导和合作在高质量安全实施RPT中的领导作用,并指出缺乏适当培训和经验实施RPT会带来显著风险。
要点
- RPT需求快速增长,可能需要数百个新中心和更多专家来实施治疗。
- 所有核医学团队成员需通过特定培训项目认证,以最小化风险并个体化调整操作。
- 缺乏适当培训和经验实施RPT会显著影响患者安全、疗效和整体照护质量。
核心结论
- 核医学和核医学专业人员在通过特定培训、教育、监管指导和合作高质量安全实施RPT中发挥领导作用。
- 缺乏适当培训和经验实施RPT会显著影响患者结局、安全、疗效和整体照护质量。
研究设计与样本
- 该文件为SNMMI立场文件,基于历史回顾和现状分析阐述观点。
主要发现
- 诊疗一体化领域可追溯至80多年前Hertz和Roberts首次使用放射性碘治疗甲状腺疾病。
- 近期神经内分泌肿瘤和前列腺癌的诊疗一体化获批扩大了RPT的使用,且近期在多瘤种中有显著扩展潜力。
- RPT需求和实施快速增长可能催生数十万个治疗周期,并需要数百个新中心和更多专家。
- 扩展将涉及整个SNMMI会员,包括医师、技师、放射化学家、物理师、放射药师、科学家和 allied health professionals。
关键数值与推荐
- 所有核医学团队成员需通过特定培训项目认证,涵盖诊疗一体化放射性药物的选择和使用。
- SNMMI已设立RPT卓越中心,并与国际认证委员会(IAC)合作建立实施RPT设施的认证项目。
- SNMMI通过临床试验网络(CTN)和治疗临床试验网络(TCTN)支持临床试验中评估RPT患者所用成像设备的研究和质量保证。
临床怎么用
- 核医学专业人员应通过特定培训和教育获得实施RPT的资质,以最小化风险并个体化调整操作。
- 实施RPT的设施可寻求SNMMI RPT卓越中心或IAC认证项目的认证。
- 利用SNMMI标准和临床指南以及国际合作确保最佳实践和知识共享。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The field of theranostics dates back over 80 y, when Hertz and Roberts first used radioactive iodine to treat thyroid disease. Recent theranostic approvals for neuroendocrine tumors and prostate cancer have expanded the use of radiopharmaceutical therapy (RPT), and there is significant near-term potential for further expansion across multiple tumor types. This Society of Nuclear Medicine and Molecular Imaging (SNMMI) position paper emphasizes the leadership role of nuclear medicine and nuclear medicine professionals in the high-quality and safe delivery of RPT through specific training, education, regulatory guidance, and collaborations. The rapidly increasing demand for access to and delivery of radiopharmaceuticals has the potential to spur hundreds of thousands of cycles of RPT, with the resultant need for hundreds of new centers and more experts to deliver these therapies. Such an expansion would involve the entire SNMMI membership, including physicians, technologists, radiochemists, physicists, radiopharmacists, scientists, and allied health professionals. All nuclear medicine team members are accredited by specific training programs covering the selection and use of radiopharmaceuticals for theranostics to minimize risks and tailor procedures to the needs of individual patients. The administration of RPT without appropriate training and experience poses significant risks in terms of patient outcomes, impacting safety, efficacy, and overall quality of care. For over 70 y, SNMMI has set comprehensive standards and clinical guidelines for the entire field of nuclear medicine, including RPT, which undergo continual review and updating. Recently, SNMMI established RPT Centers of Excellence and, in collaboration with the International Accreditation Commission (IAC), an accreditation program for facilities administering RPT. Through the Clinical Trials Network (CTN) and Therapy Clinical Trials Network (TCTN), the SNMMI also supports research and quality assurance for imaging cameras used to evaluate patients receiving RPT in clinical trials. Furthermore, collaborations with other international nuclear medicine societies ensure the continual promotion of best practices and knowledge sharing to advance the field of nuclear medicine globally.
引用
- Jacene HA, Urbain JL, Lewis JS, et al. Radiopharmaceutical Therapy: Rapid Growth, Rising Challenges, and the Critical Need for Expertise. J Nucl Med. 2025. PMID: 41130794. doi:10.2967/jnumed.125.271028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。